Bolder BioTechnology announces positive preclinical data for BBT-032 to inhibit growth of the SARS-CoV-2 virus
BOULDER -- Bolder BioTechnology, Inc . today announced preclinical studies have shown its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in... Read More
Wednesday August 26, 2020
Bolder BioTechnology awarded $593K to research radiation exposure
BOULDER -- Bolder BioTechnology, Inc. announced it received a two-year Small Business Innovation Research Grant totaling$593,507from the National Institute of Allergy and Infectious Diseases... Read More
Tuesday July 23, 2019
Bolder BioTechnology announces positive results for cancer treatment drug
BOULDER -- Bolder BioTechnology, Inc. announced it has completed a Phase 1 clinical trial of BBT-015, a proprietary long-acting granulocyte colony-stimulating factor (G-CSF) analog, in healthy... Read More
Tuesday May 1, 2018